摘要
目的采用卫生经济学中的成本-效用分析方法,评价本维莫德对比卡泊三醇治疗轻中度寻常型银屑病的经济性,为医保决策提供科学依据。方法从医保支付者视角出发,构建决策树模型,对本维莫德相比于卡泊三醇治疗轻中度寻常型银屑病患者进行成本-效用分析,评估时间为1年。采用单因素敏感性分析和概率敏感性分析来评估模型结论的可靠性。其中,成本数据来源于药品中标价格,疗效和效用值数据来源于已公开发表的文献和国内相关统计数据。结果基础分析中,本维莫德组相比于卡泊三醇组的增量成本-效用比(ICUR)为-21806元/QALY,具有绝对成本-效用;概率敏感性分析中,在目前阈值条件下(2019年中国1.5倍人均国内生产总值(GDP)为106338元),本维莫德相比于卡泊三醇具有成本-效用的概率为100%。结论在中国成本环境中,对于轻中度寻常型银屑病患者,本维莫德相比于卡泊三醇的成本低,效果好,为绝对优势方案。
Objective To conduct a cost-effectiveness analysis of benvitimod compared with calcipotriol in the treatment of mild-to-moderate plaque psoriasis to support decision-making for the inclusion of product listing in the national health insurance.Methods A decision-tree model was developed to compare cost-effectiveness of benvitimod and calcipotriol for mild-to-moderate plaque psoriasis from the payer perspective.The time horizon of the model was 1 year.Sensitivity analyses and scenario analyses were performed.The cost data for drugs was obtained from the related bidding price.The efficacy and utility data were derived from the literature and public domain statistical data.Results In the base-case analysis,the incremental cost-effectiveness ratio(ICUR)of benvitimod compared to calcipotriol was-21 806 RMB/QALY.Probabilistic sensitivity analysis indicated that the probability of benvitimod being cost-effectiveness was 100% compared to calcipotriol under the current recommended willingness-to-pay threshold(1.5 times GDP per capita was 106 338 RMB in 2019).Conclusion Benvitimod is dominantly cost-effective in the treatment of mild-to-moderate plaque psoriasis compared with calcipotriol in Chinese population.
作者
陈婉欣
张玥
林志远
肖敦明
邱童
宣建伟
CHEN Wan-Xin;ZHANG Yue;LIN Zhi-Yuan;XIAO Dun-Ming;QIU Tong;XUAN Jian-Wei(School of pharmacy,Sun Yat-sen University,Guangzhou 510006,China;Shanghai shengtani Pharmaceutical Technology Co.,Ltd.,Shanghai 200030,China;Guangdong Zhonghao Pharmaceutical Co.,Ltd.,Zhongshan 528437,China)
出处
《中国药物经济学》
2022年第6期5-9,共5页
China Journal of Pharmaceutical Economics
作者简介
通信作者:宣建伟,E-mail:jwx02467@gmail.com。
